Knight Therapeutics commits $35 mln to Domain, Sanderling funds
Canadian specialty pharmaceutical company Knight Therapeutics Inc (TSX: GUD) has committed a total of US$35 million to new funds managed by U.S. life sciences venture capital firms Domain Associates and Sanderling Ventures. The fund commitments, which follow the company's $30 million commitment in October to Teralys Capital Innovation Fund LP, a life sciences fund managed by Canadian fund of funds manager Teralys Capital, reflect Knight Therapeutics' continuing product sourcing strategy.
16 December 2014•3 mins read
